The mechanism of action of chromium rich yeast

Chromium and lipid metabolism
The relationship between chromium and lipid metabolism has been extensively studied both domestically and internationally: chromium supplementation can have beneficial regulatory and improvement effects on the body's lipid metabolism by regulating the content of various lipoproteins and cholesterol metabolism; Supplementing animal diets with chromium can reduce the levels of serum triglycerides and total cholesterol, and increase the levels of high-density lipoprotein (HDL). Chromium may regulate lipid metabolism through two mechanisms. One is that dietary supplementation of chromium can increase insulin activity (which decreases when chromium is deficient and induces lipid metabolism disorders through glucose metabolism), regulate lipid metabolism, and improve the body's blood lipid status. Therefore, it is related to the occurrence of human coronary heart disease, hyperlipidemia, and arteriosclerosis; Secondly, chromium can enhance the activity of lipoprotein lipase (LPL) and lecithin cholesterol acyltransferase (LCAT), which play important roles in the synthesis of HDL. When the body lacks chromium, the synthesis and content of HDL decrease.
Some evidence suggests that chromium can increase the breakdown and excretion of cholesterol. Abraham et al. (1980) demonstrated that chromium not only reduces cholesterol deposition on the rabbit aorta, but also clears cholesterol deposited on the aorta. Page (1993) added different levels of Picolinate Chromium to the diet of growing and fattening pigs, significantly reducing cholesterol levels in pig serum. Lein (1996) added 200ppb of chromium (GrPic) to the feed of growing pigs, which significantly reduced serum triglycerides and low-density lipoprotein cholesterol (P<0.05), and significantly increased creatine liver and high-density lipoprotein (HDL) (P<0.05). Pahe et al. (1991) reported that adding 200pp chromium picolinate to the diet of laying hens resulted in a decrease in cholesterol in the blood, but no change in cholesterol in the egg yolk. Based on relevant research results, chromium may regulate lipid metabolism through two pathways. On the one hand, when animals are deficient in chromium, the biological activity of insulin decreases, glucose tolerance is impaired, and lipid metabolism disorders are caused by glucose metabolism. After chromium supplementation, insulin activity is enhanced, cholesterol deposition in the aorta is reduced, lipid metabolism is regulated, and lipid status is improved; On the other hand, chromium can enhance the activity of lipoproteins and lecithin cholesterol acyltransferase, thereby enhancing the synthesis of high-density lipoprotein. When animals lack chromium, the activity of these two enzymes decreases, leading to a decrease in high-density lipoprotein synthesis and a decrease in high-density lipoprotein in the blood.
The elderly are prone to diabetes and atherosclerosis when they lack chromium, and can also cause hyperlipidemia, arterial Congee, growth retardation and shortened life span. Chromium supplementation has the effect of reversing the above phenomenon.
The hypoglycemic effect of chromium
A large number of studies have shown that trivalent chromium in the body will lead to glucose and lipid metabolism disorder. Chromium deficiency in human body is closely related to diabetes and its complications. It is believed that the mechanism of action of chromium is to increase the binding affinity between pancreatic beta receptors, increase the number of pancreatic beta receptors, and enhance the phosphorylation of pancreatic beta receptors. In addition, chromium mainly assists pancreatic islet dysfunction in glucose intake, glucose oxidation to CO, and glucose conversion to fat, as well as in the metabolism of sugars, proteins, and fats dependent on pancreatic islet dysfunction. The role of the discovered natural low molecular weight chromium binding substance (LMWCr) in regulating pancreatic dysregulation is gradually being recognized. Chromium can activate the activity of insulin receptor kinase. In the presence of insulin kinase, LMWC can stimulate kinase activity by 8 times. However, separating chromium from it will eliminate its effect of increasing enzyme activity. Chromium can also inhibit the phosphorylation of tyrosine phosphate
Phosphatase, which can reduce the activity of pancreatic beta receptors.
The activation of pancreatic beta kinase by chromium and the inhibition of pancreatic beta tyrosine phosphatase lead to increased phosphorylation of pancreatic beta kinase and increased sensitivity to pancreatic beta kinase.
The recommended daily chromium intake standard internationally is 50-200 micrograms. Studies have shown that chromium supplementation is effective in the treatment of different types of diabetes (including type 2 diabetes, type 1 diabetes, pregnancy diabetes and steroid induced diabetes). Chromium deficiency exists in diabetic patients. The effect of using organic chromium is better than inorganic chromium. Common organic chromium includes chromium picolinate, chromium nicotinate, chromium yeast, etc.